Biophytis – Second Combined General Meeting to Take Place on May 10, 2021 without the physical presence of its shareholdersRead the press release

Biophytis receives €980,000 DeepTech Funding from BPI France for the Development of Macuneos (BIO201) in Dry AMDRead the press release

Biophytis – Convening of Another Combined General Meeting at a Later DateRead the press release 

Biophytis gives operational perspectives on its Sarconeos (BIO101) ahead of its upcoming AGM on April 26, 2021Read the presse release

Interview of Stanislas Veillet, CEO of Biophytis on La Bourse ou la Vide.com (in French).

Watch the Video

Biophytis Identifies False Report Regarding COVA StudyRead the Press Release

Stanislas Veillet, CEO of Biophytis, reviews the company’s latest news in this interview with Laurent Grassin from Journal des Biotechs, covering listing on Nasdaq, Covid-19 clinical studies, expected clinical data in sarcopenia and the legal case with Negma.  You can see the interview here

Biophytis gives updates on its Phase 2-3 COVA study on COVID-19

Read the Press Release

Judgment of the Paris Commercial Court of March 16, 2021 in the case of Biophytis against Negma Group Ltd

Read the press release

Biophytis AGM meeting will take place on April 26, 2021. Read the Press Release

Biophytis Reports 2020 Full Year Results. Read the Press Release

Biophytis Announces Expansion of Patient Recruitment for Part 2 of the Phase 2-3 COVA Trial (“COVA Study”) following Regulatory Authorities approvals in France and Belgium. Read the Press Release

Biophytis Announces Closing of ADS Offering on Nasdaq Capital Market. Read the Press Release

Biophytis Announces Trading Resumption of its Ordinary Shares and Share Warrants on Euronext.Read the Press Release 

Biophytis Announces Temporary Trading Halt of its Shares and Share Warrants on Euronext Growth. Read the Press Release

Biophytis Announces Pricing of $20.1 Million U.S. Initial Public Offering of American Depositary Shares and Approval to List on Nasdaq Capital Market. Read the Press Release

Biophytis Announces the Launch of its Proposed Public Offering and Nasdaq Listing. Read the Press Release

Biophytis Announces the Start of Patient Recruitment in Brazil and the USA for Part 2 of the Phase 2-3 COVA Trial (“COVA Study”). Read the Press Release

Biophytis Announces Public Filing of a Registration Statement for Proposed Initial Public Offering in the United States. Read the Press Release

Biophytis Announces Plan to Publicly File Later Today Registration Statement for Proposed Initial Public Offering in the United States. Read the Press Release

Biophytis receives DMC recommendation for starting recruitment for Part 2 of its Phase 2-3 COVA study in COVID-19. Read the Press Release

Biophytis to Participate in Upcoming Investor & Partnering Conferences During J.P. Morgan Week 2021. Read the Press Release